With ongoing research about the cytokine patterns and immunological characteristics of psoriasis, the development of targeted systemic therapies became possible, and in the last decade, we have experienced a variety of options for systemic psoriasis medications for adults targeting the inflammatory cascade with biological disease-modifying antirheumatic drugs (bDMARDs); TNF-α blockers; interleukin (IL)-17, IL-12/23, or -23 inhibitors; phosphodiesterase inhibitors; and recently Janus kinase inhibitors (JAK inhibitors) [24]. The gene discussed is TNF; the disease is psoriasis.